Myriad Genetics, Inc. (MYGN) myPlan™ Lung Cancer Test Launched to Leading Oncologists
10/29/2013 9:21:01 AM
SALT LAKE CITY, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has launched a new prognostic test, Myriad myPlan Lung Cancer, for patients diagnosed with early-stage lung adenocarcinoma. myPlan Lung Cancer is an RNA expression panel of 31 cell-cycle-progression genes, in combination with tumor staging information, to determine a patient's risk of dying from lung cancer within five years.
Help employers find you! Check out all the jobs and post your resume.
comments powered by